Viral Conjunctivitis

01/01/2019 - "Patients with signs of acute viral conjunctivitis at the Day 6 visit received open-label PVP-I/DEX for five additional days and were evaluated on Day 11-14. "
01/01/1997 - "Although no commercial product for repeated application on the eye is currently available, PVP-I has been used in ophthalmology not only for pre- and postoperative antisepsis, but also for the treatment of bacterial and viral conjunctivitis and for prophylaxis against ophthalmia neonatorum. "
01/01/2019 - "Adults with a clinical diagnosis of suspected acute viral conjunctivitis were randomized 1:1 to PVP-I/DEX ophthalmic suspension or vehicle bilaterally four times daily for 5 days (Days 1-5). "
01/01/2019 - "To evaluate the clinical safety and efficacy of povidone-iodine (PVP-I) 0.6%/dexamethasone (DEX) 0.1% ophthalmic suspension vs vehicle in patients with clinically suspected acute viral conjunctivitis. "
01/01/2019 - "A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis."

01/01/2022 - "Antibiotic use as a prerequisite for return to school has drawbacks of cost to parents, increasing antibiotic resistance, and lack of efficacy against nonbacterial etiologies, for example, viral conjunctivitis. "
10/01/2023 - "Microbiological spectrum and antibiotic susceptibility patterns of non-viral conjunctivitis over 16 years at a tertiary eye care center in Southern India."
12/01/2020 - "After no improvement on antibiotics, both patients were noted to have exam findings consistent with viral conjunctivitis, and one patient had a positive conjunctival swab for adenovirus. "
12/01/2019 - "Patients with viral conjunctivitis typically presented within a week of symptom onset, with bilateral disease and on topical antibiotics. "
07/01/2017 - "True diagnosis plays an important role on prevention of contamination and unnecessary use of antibiotics in viral conjunctivitis."

12/01/2020 - "To determine whether topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin/dexamethasone eye drops alone. "
12/01/2020 - "The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial."
05/01/1997 - "Seventy-five patients (146 eyes) with viral conjunctivitis were randomly assigned to receive topical antibiotic (35 cases) or antibiotic combined with piroxicam eye drops (40 cases). "
09/01/2015 - "Dexamethasone/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial."
11/01/2002 - "Povidone-iodine 1.25% ophthalmic solution was as effective as neomycin-polymyxin B-gramicidin for treating bacterial conjunctivitis, somewhat more effective against chlamydia, and as ineffective against viral conjunctivitis. "

10/01/2017 - "Symptomatic Treatment of Subepithelial Infiltrates after Viral Conjunctivitis: Loteprednol or Dexamethasone?"
01/01/2019 - "To evaluate the clinical safety and efficacy of povidone-iodine (PVP-I) 0.6%/dexamethasone (DEX) 0.1% ophthalmic suspension vs vehicle in patients with clinically suspected acute viral conjunctivitis. "
12/01/2020 - "To determine whether topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin/dexamethasone eye drops alone. "
12/01/2020 - "The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial."
01/01/2019 - "A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis."

01/01/2019 - "Adults with a clinical diagnosis of suspected acute viral conjunctivitis were randomized 1:1 to PVP-I/DEX ophthalmic suspension or vehicle bilaterally four times daily for 5 days (Days 1-5). "
01/01/2019 - "To evaluate the clinical safety and efficacy of povidone-iodine (PVP-I) 0.6%/dexamethasone (DEX) 0.1% ophthalmic suspension vs vehicle in patients with clinically suspected acute viral conjunctivitis. "
01/01/2019 - "A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis."

11/01/2002 - "Povidone-iodine 1.25% ophthalmic solution was as effective as neomycin-polymyxin B-gramicidin for treating bacterial conjunctivitis, somewhat more effective against chlamydia, and as ineffective against viral conjunctivitis. "

11/01/2002 - "Povidone-iodine 1.25% ophthalmic solution was as effective as neomycin-polymyxin B-gramicidin for treating bacterial conjunctivitis, somewhat more effective against chlamydia, and as ineffective against viral conjunctivitis. "

11/01/2002 - "Povidone-iodine 1.25% ophthalmic solution was as effective as neomycin-polymyxin B-gramicidin for treating bacterial conjunctivitis, somewhat more effective against chlamydia, and as ineffective against viral conjunctivitis. "

07/01/2012 - "A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis."
09/01/2011 - "A randomised placebo-controlled trial of topical steroid in presumed viral conjunctivitis."
12/01/2019 - "To find correlations between viral and patient characteristics on disease outcomes and to assess the rates of antibiotic and steroid use in patients with viral conjunctivitis prior to and after assessment by ophthalmology trainees. "
09/01/2011 - "To assess whether topical steroids improve patient comfort compared with hypromellose in acute presumed viral conjunctivitis. "

03/01/2015 - "Adenoviral DNA was detected by PCR in 213 of 488 (44%) of the ocular samples collected from patients with viral conjunctivitis during the 5-year study period. "
02/01/2008 - "The present study was carried out to explore the presence of Ad as a causative agent in clinically suspected viral conjunctivitis and to compare the performance of conventional virus isolation on cell cultures, direct detection of Ad antigens in conjunctival cells by a direct fluorescence assay, Ad DNA detection by polymerase chain reaction (PCR), and specific IgM measurement by ELISA. "

11/01/2023 - "[Viral Conjunctivitis: Findings, Therapy, and Prophylaxis]."
07/01/1993 - "Most bacterial and viral conjunctivitis are self-limited, but antimicrobial therapy for the former is advocated to shorten the course, improve patient comfort, prevent recurrence, avoid complications and limit spread to other individuals."
01/01/2008 - "This article presents one of the physical medicine's methods--magnetotherapy--which uses the alternating low frequency magnetic fields in the therapy of viral conjunctivitis and keratitis in a 49-year-old female patient. "
07/03/2009 - "In particular, we discuss clinical predictors of bacterial versus viral conjunctivitis, a potential role for routine conjunctival culture, the benefits of topical antibiotic therapy for bacterial infections, delayed treatment algorithms, choice of topical antibiotic and the restriction of selected patients from work, school or early childhood care."

01/01/2008 - "Magnetotherapy in the treatment of viral conjunctivitis and keratitis."
01/01/2008 - "This article presents one of the physical medicine's methods--magnetotherapy--which uses the alternating low frequency magnetic fields in the therapy of viral conjunctivitis and keratitis in a 49-year-old female patient. "

01/01/1999 - "To report the recurrence of presumed post-viral conjunctivitis subepithelial corneal opacities after excimer laser phototherapeutic keratectomy (PTK). "

08/30/2008 - "Patients who have viral conjunctivitis after LASIK surgery should be examined carefully and managed with consideration of flap complications."
08/30/2008 - "Delayed epithelial ingrowth caused by viral conjunctivitis after LASIK."

01/01/2020 - "We report a rare case of very late-onset haze triggered by viral conjunctivitis, > 20 years after treatment of moderate myopia with photorefractive keratectomy (PRK), and its successful management."